Our experienced healthcare providers are committed to monitoring your progress closely through regular follow-up appointments, adjusting your treatment plan as needed, and providing guidance to help you achieve your health goals effectively
Idiopathic intracranial hypertension is a condition characterized by increased pressure inside the skull without an obvious cause, often resulting in severe headaches and vision problems
Nine states provided coverage under their Medicaid programs
At the same time, we are facing an exciting multifaceted future, with several novel developments on the horizon with the potential to change the clinic setting, including the development of oral GLP-1 receptor agonists and the emerging formulations of GIP receptor agonists and dual and triple receptor agonists, which have shown clear therapeutic potential
As the discontinuation rates were also high with the twice daily danuglipron at the phase 2 obesity trial (as discussed above), twice daily danuglirpon formulation will not advance into phase 3 studies, but an improved once-daily formulation with an aim to improve tolerability profile is currently under assessment [27]
